FDA Approves Ipilimumab for Pediatric Melanoma

July 24, 2017 – The FDA has approved ipilimumab for the treatment of patients aged ≥12 years with unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor. The expanded indication for ipilimumab is based on data across 2 trials in which objective responses were observed in 2 of 17 patients aged ≥12 years with advanced melanoma. The responses included 1 partial response that lasted … (leggi tutto)